MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Altimmune Market Cap 2011-2025 | ALT
As of December 25, 2025 Altimmune has a market cap of $ 283 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Altimmune
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 463 M | 473 M | 593 M | 333 M | 472 M | 23.2 M | 9.3 M | 23.4 M | 5.66 K | 3.31 M | 4.03 M | 443 K | 362 K | 189 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 593 M | 5.66 K | 171 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
445 M | $ 4.79 | 2.35 % | $ 795 M |  Canada |
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B |  USA |
 |
Aclaris Therapeutics
ACRS
|
152 M | $ 3.04 | 4.83 % | $ 235 M | USA |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Aptorum Group Limited
APM
|
4.09 M | $ 1.17 | 4.46 % | $ 6.38 M |  China |
 |
Aptevo Therapeutics
APVO
|
889 K | $ 0.93 | -8.81 % | $ 257 K | USA |
 |
Athersys
ATHX
|
364 M | - | 3.77 % | $ 22.4 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioVie
BIVI
|
2.44 M | $ 1.27 | -3.05 % | $ 1.88 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
8.32 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
117 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
67 M | - | - | $ 546 M | USA |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 212.81 | 1.71 % | $ 5 B |  Danmark |
 |
Calithera Biosciences
CALA
|
960 M | - | -10.95 % | $ 876 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 0.18 | -25.03 % | $ 392 M |  Israel |
|
Cerevel Therapeutics Holdings
CERE
|
6.68 B | - | - | $ 7.29 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.1 | 0.16 % | $ 7.46 B |  Australia |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Catalyst Biosciences
CBIO
|
33.6 M | $ 12.37 | 2.06 % | $ 814 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M | Britain |
 |
Celsion Corporation
CLSN
|
21.1 M | - | -6.63 % | $ 13.9 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 95.03 | 0.95 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
1.31 B | $ 26.81 | 1.36 % | $ 1.3 B | USA |
 |
Anika Therapeutics
ANIK
|
373 M | $ 9.48 | 0.96 % | $ 139 M | USA |
 |
Cortexyme
CRTX
|
70 M | - | -1.05 % | $ 67.1 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
551 M | - | - | $ 1.2 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
39.8 B | $ 591.15 | 0.02 % | $ 44.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.53 | -0.39 % | $ 15.9 M | USA |
 |
AstraZeneca PLC
AZN
|
81.2 B | $ 92.45 | 0.34 % | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
1.31 M | $ 26.83 | 0.94 % | $ 1.73 M | USA |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 9.0 | -1.32 % | $ 1.48 B | Britain |